This effect is thought to be due to mu-opioid receptor activity as evidenced in one study by improved survival in colorectal and breast cancer patients receiving mu-opioid receptor antagonists, such as naloxone (44, 45). The gene discussed is OPRM1; the disease is breast cancer.